Clinical Trials Logo

Malignant Carcinoid Syndrome clinical trials

View clinical trials related to Malignant Carcinoid Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05361668 Active, not recruiting - Carcinoid Tumor Clinical Trials

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Start date: June 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

NCT ID: NCT05064514 Active, not recruiting - Clinical trials for Tricuspid Regurgitation

Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease

TRICAR
Start date: April 6, 2022
Phase: N/A
Study type: Interventional

The purpose of this investigation is to see if the TRICENTO Valved Stent Graft implant reduces tricuspid regurgitation (TR) and improves the symptoms and quality of life in 15 participants with carcinoid heart disease, and who are not able to have a new valve via a surgical procedure.

NCT ID: NCT03375320 Active, not recruiting - Carcinoid Tumor Clinical Trials

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Start date: October 26, 2018
Phase: Phase 3
Study type: Interventional

This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

NCT ID: NCT01841736 Active, not recruiting - Clinical trials for Metastatic Digestive System Neuroendocrine Tumor G1

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Start date: September 20, 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00730483 Active, not recruiting - Metastatic Cancer Clinical Trials

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

Start date: February 2009
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor and kill more tumor cells. PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see how well they work in treating patients with unresectable liver metastases from neuroendocrine tumors.

NCT ID: NCT00454376 Active, not recruiting - Lung Cancer Clinical Trials

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

Start date: October 2006
Phase: Phase 4
Study type: Observational

RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors. PURPOSE: This phase IV clinical trial is studying how well a disease-specific questionnaire works in assessing the quality of life of patients with gastrointestinal-related neuroendocrine tumors.

NCT ID: NCT00436735 Active, not recruiting - Colorectal Cancer Clinical Trials

Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors

Start date: September 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors.